Home › Funds › RA CAPITAL MANAGEMENT, L.P. › JBIO

RA CAPITAL MANAGEMENT, L.P. position in JBIO

JADE BIOSCIENCES INC · Health Care

RA CAPITAL MANAGEMENT, L.P. reported holding 1,835,542 shares of JBIO (JADE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$25.8M, representing 0.27% of its reported portfolio and ranking #49 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

Latest position (Q3 2026)1.84M sh
Reported value held$25.79M
Portfolio Weight0.27%
First reportedQ2 2025
Last changeReduce
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How RA CAPITAL MANAGEMENT, L.P.'s JBIO position evolved

RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in JBIO in Q2 2025 at 1,062,326 shares (US$10.6M). The position peaked in Q2 2026 at 3,671,083 shares, worth US$81.6M. Across 6 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 1,835,542 shares valued at US$25.8M — a reduction of -1,835,541 shares quarter over quarter.. Notable position changes include a 246% increase in Q4 2025 (shares fell 9% over the following quarter), a 50% trim in Q3 2026 (shares rose 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 1.06M $10.61M New
Q3 2025 1.06M $9.17M Hold
Q4 2025 3.67M $56.64M Add
Q1 2026 3.67M $51.58M Hold
Q2 2026 3.67M $81.57M Hold
Q3 2026 1.84M $25.79M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About JBIO and 13F data

JBIO (JADE BIOSCIENCES INC) is a Health Care company. 81 other funds we track also report a position in JBIO — the largest reported positions include Paradigm Biocapital Advisors LP (US$85.0M), Fairmount Funds Management LLC (US$64.0M), Bellevue Group AG (US$60.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding JBIO

All JBIO fund holders →

FAQ

How long has RA CAPITAL MANAGEMENT, L.P. held JBIO?

RA CAPITAL MANAGEMENT, L.P. has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

What is RA CAPITAL MANAGEMENT, L.P.'s current position in JBIO?

As of Q3 2026, RA CAPITAL MANAGEMENT, L.P. holds 1.84M shares of JBIO (JADE BIOSCIENCES INC), valued at $25.79M, representing 0.27% of its reported portfolio and ranking #49.

Has RA CAPITAL MANAGEMENT, L.P. been buying or selling JBIO?

In the latest 13F filing (Q3 2026), RA CAPITAL MANAGEMENT, L.P. reduced its position in JBIO. The position peaked in Q2 2026 at 3.67M shares.

Which other funds hold JBIO?

Other major institutional holders of JBIO include Paradigm Biocapital Advisors LP, Fairmount Funds Management LLC, Bellevue Group AG, among 81 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.